

ACCP Annual Meeting Schedule of Continuing Education Activities

Target Audience

The Annual Meeting is designed for health professionals involved with clinical pharmacy—students, residents, fellows, and experienced practitioners and educators.

Program Goals

The Annual Meeting is designed for health professionals involved with clinical pharmacy—students, residents, fellows, and experienced practitioners and educators. The educational programming developed for this meeting provides attendees with new, high-quality information that will be both challenging and applicable in their practice.

Learning Objectives

Only learning objectives are supplied for sessions offered for continuing pharmacy education credit.

Saturday, October 18, 2008

8:00 a.m. – 4:00 p.m.

Controversies in Critical Care Nephrology

Developed by the Critical Care PRN and Nephrology PRN

Moderators: Michael Bentley, Pharm.D.

Assistant Professor, School of Pharmacy and Clinical Specialists,
Critical Care, Carilion Clinic, Virginia Commonwealth University,
Roanoke, Virginia

and

Robert MacLaren, Pharm.D., FCCP

Assistant Professor, School of Pharmacy, University of Colorado,
Denver, Colorado

8:00 a.m.

Introduction

Michael Bentley, Pharm.D.

8:10 a.m. Applying Definitions of Acute Renal Failure in Critically Ill Patients
Thomas C. Dowling, Pharm.D., Ph.D.
Associate Professor, Director, Renal Clinical Pharmacology Lab,
University of Maryland, Baltimore, Maryland

1. Describe the epidemiology of acute renal failure in the intensive care unit (ICU).
2. Present basic pathophysiology of acute renal failure in the ICU.
3. Differentiate methods of classifying renal function in the ICU.
 - a. RIFLE vs. MDRD vs. CrCl (MDRD and CrCl to be defined and, if appropriate, compared to RIFLE in depth discussion to follow during the Pro/Con Debate) vs.etc
 - b. Biomarkers (cystatin-C, NGAL, etc)
4. Distinguish chronic renal dysfunction from acute renal failure.

8:40 a.m. Pro/Con Debate: MDRD vs. CrCl to Assess Renal Function in Critically Ill Patients
Thomas Nolin, Pharm.D., Ph.D.
Clinical Pharmacologist, Division of Nephrology and Transplantation and Department of Pharmacy Services, Maine Medical Center, Portland, Maine

and

William Dager, Pharm.D., FCSHP
Clinical Pharmacy Specialist, Department of Pharmaceutical Services, University of California Davis Medical Center, Sacramento, California

1. Present evidence supporting the use of MDRD vs. CrCl as the primary mechanism of assessing renal function.
2. Describe advantages and disadvantages of using MDRD vs. CrCl in critically ill patients.

9:20 a.m. Methods to Prevent/Reduce Renal Dysfunction in the Critically Ill
Thomas C. Dowling, Pharm.D., Ph.D.

1. Differentiate pharmacotherapeutic (NAC, fenoldepam, NaCl, NaBicarb) and nonpharmacologic methods of maintaining renal function in critically ill patients.
2. Describe the evidence pertaining to different modalities that may be used to prevent / reduce renal dysfunction (e.g. diuretics).
3. Construct protocols for using pharmacotherapeutic and nonpharmacologic methods of preventing renal dysfunction

9:50 a.m. Break

- 10:10 a.m. Modes of Renal Support
Mariann Churchwell, Pharm.D., BCPS
Assistant Professor, The University of Toledo, College of Pharmacy, Department of Pharmacy Practice, Toledo, Ohio
1. Compare and contrast intermittent support from continuous support.
 2. Differentiate CVVH, CVVHD, CVVHDF, EDD/SLED and high volume hemofiltration in terms of modes of support, and replacement fluids.
 3. Provide case examples of when each mode may be warranted.
- 10:50 a.m. Drug Dosing Strategies for Renal Support
William Dager, Pharm.D., FCSHP
1. List factors that influence drug removal, e.g. sieving coefficient and saturation coefficient.
 2. Differentiate drug dosing and provide drug dosing recommendations for each mode of renal support.
- 11:30 a.m. Lunch
- 12:30 p.m. Welcome Back
Robert MacLaren, Pharm.D., FCCP
- 12:40 p.m. Anticoagulant Strategies for Renal Support
Tyree Kiser, Pharm.D., BCPS
Assistant Professor, University of Colorado School of Pharmacy, Denver, Colorado
1. Compare and contrast anticoagulation options (citrate, heparin, DTI, none, other) using sustained low-efficiency dialysis and continuous renal replacement therapies.
 2. Discuss rationale for choosing the different anticoagulants

1:20 p.m.

Cases

Moderators: Michael Bentley, Pharm.D.

Assistant Professor, School of Pharmacy and Clinical Specialists,
Critical Care, Carilion Clinic, Virginia Commonwealth University,
Roanoke, Virginia

and

Robert MacLaren, Pharm.D., FCCP

Assistant Professor, School of Pharmacy, University of Colorado,
Denver, Colorado

1. Describe SLED therapy using a case format.
2. Allow the participants to list and describe anticoagulant choices for SLED.
3. Allow the participants to develop and present drug dosing strategies given two to three medications
4. Describe CRRT using a case format.
5. Allow the participants to list and describe an anticoagulant choice for CRRT.
6. Allow the participants to develop and present drug dosing strategies given two to three medications.

2:40 p.m.

Hepatorenal syndrome

Tyree Kiser, Pharm.D., BCPS

1. Describe the pathophysiology and epidemiology of hepatorenal syndrome.
2. Differentiate pharmacotherapeutic (octreotide, vasopressin and analogues, dopamine, other pressors) and nonpharmacologic methods of managing hepatorenal syndrome.
3. Describe and speculate about the use of hepatic support systems (MARS).

3:00 p.m.

Influence of Kidney Disease and Renal Replacement Therapy on Hepatic Function

Thomas Nolin, Pharm.D., Ph.D.

1. Describe the influences of kidney dysfunction and renal support on hepatic function.
2. Describe how the liver influences the elimination of drugs cleared by the kidney.
3. Provide strategies to account for this influence.

3:30 p.m.	<p>Nutritional and Electrolyte Issues During Renal Dysfunction and Support <i>Mariann Churchwell, Pharm.D., BCPS</i></p>
	<ol style="list-style-type: none"> 1. Describe the nutritional and electrolyte considerations that should be taken into account when patients have acute renal dysfunction or require renal support. 2. Provide case examples of these considerations. 3. Construct protocols for appropriate nutritional and electrolyte regimens in patients with acute renal dysfunction or requiring renal support.
8:00 a.m. – 5:00 p.m.	<p>Research Primer <i>Part of the ACCP Academy Research and Scholarship Development Certificate Program. For more information visit the Web site at http://academy.accp.com/.</i></p> <p><i>Moderator: Gary C. Yee, Pharm.D., FCCP, BCOP</i> Professor, University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska</p>
8:00 a.m.	<p>Welcome and Overview of the Academy Program <i>Gary C. Yee, Pharm.D., FCCP, BCOP</i></p>
8:15 a.m.	<p>Introduction to Clinical Research <i>Gary C. Yee, Pharm.D., FCCP, BCOP</i></p>
	<p>Learning Objectives:</p> <ol style="list-style-type: none"> 1. Describe the basic types of clinical research. 2. Describe the differences between T1 and T2/T3 clinical research.
9:00 a.m.	<p>Anatomy of a Research Project <i>Michael E. Klepser, Pharm.D., FCCP</i> Ferris State University, Kalamazoo, Michigan</p>
	<p>Learning Objectives:</p> <ol style="list-style-type: none"> 1. Describe the various components of a research proposal and the purpose of each component. 2. List the questions that are addressed with each component of the proposal. 3. Describe how research proposals differ depending on the funding agency (e.g., institutional, professional association, industry).
10:00 a.m.	Break

10:15 a.m.	<p>How to Develop a Research Question and Write the Background and Significance <i>Gary C. Yee, Pharm.D., FCCP, BCOP</i></p> <p>Learning Objectives:</p> <ol style="list-style-type: none"> 1. Describe the origins of a research question. 2. List the FINER criteria for a good research question. 3. Use the FINER criteria to develop a focused research question. 4. Describe the differences between a hypothesis, research question, and specific aims. 5. Describe the purpose and importance of the background and significance section.
11:00 a.m.	Lunch Break (on your own)
12:30 p.m.	Small Group Discussion
3:00 p.m.	<p>How to Find a Mentor and Assemble a Research Team <i>Susan C. Fagan, Pharm.D., FCCP, BCPS</i> Professor, Clinical and Administrative Pharmacy, University of Georgia, Augusta, Georgia</p> <p>Learning Objectives:</p> <ol style="list-style-type: none"> 1. Explain how to select a mentor that will enhance your professional development. 2. List the roles and responsibilities of the principal investigator and other members of the research team. 3. Describe ways to best manage your role within the research team. 4. List possible resources for finding research team partners (e.g., biostatistics). 5. Describe guidelines for authorship.
4:00 p.m.	<p>Tips on Scientific Writing <i>Richard T. Scheife, Pharm.D., FCCP</i> Editor, Pharmacotherapy, Boston, Massachusetts</p> <p>Learning Objectives:</p> <ol style="list-style-type: none"> 1. Discuss the basic principles of scientific writing. 2. Describe the ways in which scientific writing differ from other writing styles. 3. Describe practical ways to improve scientific writing skills. 4. List useful resources for scientific writing.
5:00 p.m.	Wrap-Up

8:00 a.m. – 5:30 p.m.

Basic Training for New Clinical Faculty and Preceptors

Part of the ACCP Academy Teaching and Learning Certificate Program. For more information visit the Web site at <http://academy.accp.com/>.

Moderator: Thomas D. Zlatic, Ph.D.

Professor, St. Louis College of Pharmacy, St. Louis, Missouri

Faculty: Jack M. Burke, Pharm.D., FCCP, BCPS

Professor of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, Missouri

Dana Hammer, Ph.D.

Director, Bracken Pharmaceutical Care Learning Center, University of Washington School of Pharmacy, Seattle, Washington

Sheldon G. Holstad, Pharm.D.

Professor and Associate Director, Division of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, Missouri

Julie A. Murphy, Pharm.D., BCPS

Assistant Professor of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, Missouri

Thomas D. Zlatic, Ph.D.

Learning Objectives:

1. Describe basic concepts related to current pedagogical theory and practice as they pertain to pharmacy education and practice.
2. Develop basic strategies for planning, implementing, and assessing educational experiences which are structured to achieve clearly defined student outcomes within didactic and clinical settings.
3. Clarify one's own purposes, goals, and philosophy for teaching, and identify strategies for continued self-learning.

8:00 a.m.	Teaching for Outcomes
8:15 a.m.	Raising the Goals: Critical Thinking and Problem Solving
9:00 a.m.	Teaching Ability Outcomes
9:45 a.m.	Break
10:00 a.m.	Active Learning to Achieve Abilities
11:00 a.m.	Lunch Break
12:30 p.m.	Small Groups
1:00 p.m.	Assessing Student Performance
2:00 p.m.	Small Groups

2:30 p.m.	Share and Critique Small Group Work on Assessment
2:45 p.m.	Break
3:00 p.m.	Teaching as a Profession in the 21st Century
3:30 p.m.	Clarifying One's Teaching Goals: Portfolios
5:00 p.m.	Summary, Questions, Assignments
12:00 p.m. – 5:00 p.m.	<p>Current Topics in Ambulatory Cardiology <i>Developed by the Ambulatory Care PRN and the Cardiology PRN Supported by an educational grant from AstraZeneca</i></p> <p><i>Moderators: Sheryl L. Chow, Pharm.D., BCPS</i> Assistant Professor of Pharmacy Practice, Western University of Health Sciences, Pomona, California</p> <p>and</p> <p><i>Alan Zillich, Pharm.D.</i> Assistant Professor of Pharmacy Practice, Purdue University, Indianapolis, Indiana</p> <p>Learning Objectives:</p> <ol style="list-style-type: none"> 1. Compare and contrast scientific evidence for achieving blood pressure goals. 2. Discuss the evidence supporting therapy targeting multiple sites of inhibition along the renin-angiotensin-system (RAS). 3. Provide appropriate therapeutic recommendations and clinical pearls for the medical management of heart failure patients. 4. Discuss current recommendations for anticoagulation based on the 2008 Chest Guidelines. 5. Create a therapeutic plan that will optimize both LDL and HDL cholesterol. 6. Discuss therapeutic options for anti-ischemic management of patients with CAD. 7. Discuss current controversies and advances in the management of patients with CAD.
12:00 p.m.	<p>Introduction <i>Sheryl L. Chow, Pharm.D., BCPS</i></p> <p>and</p> <p><i>Alan Zillich, Pharm.D.</i></p>
12:05 p.m.	<p>BP Treatment Goals for Special Populations—A Lower Threshold and How to Achieve Them <i>William Cushman, M.D.</i> Professor of Medicine and Preventive Medicine, University of Tennessee, Memphis, Tennessee</p>

- 1:00 p.m. Evidence for Combined RAS Blockade with ACEI/ARB and/or Direct Renin Inhibition
Mark Munger, Pharm.D., FCCP
Professor of Pharmacotherapy and Associate Dean, College of Pharmacy, University of Utah, Salt Lake City, Utah
- 1:45 p.m. Practical Approach to the Management of Chronic HF Medications
Jo Ellen Rodgers, Pharm.D., BCPS (AQ Cardiology)
Clinical Assistant Professor, Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina
- 2:30 p.m. Break
- 2:45 p.m. Optimizing the Management of Patients with CAD
Toby C. Trujillo, Pharm.D., BCPS
Clinical Coordinator-Residency Training and Academic Affairs and Clinical Specialist-Cardiology/Anticoagulation, Boston Medical Center; Clinical Associate Professor, Northeastern University School of Pharmacy, Boston, Massachusetts
- 3:30 p.m. Achieving Optimal Lipid Treatment: The Benefits of Attaining Both LDL and HDL Cholesterol Goals
Eric Gupta, Pharm.D., BCPS
Assistant Professor of Pharmacy Practice, Western University of Health Sciences, College of Pharmacy, Pomona, California
- 4:15 p.m. 2008 Chest Guidelines Update on Anticoagulation
Ann Wittkowsky, Pharm.D., CACP, FCCP, FASHP
Clinical Professor, University of Washington, School of Pharmacy, Seattle, Washington
- 4:55 p.m. Closing Remarks
Sheryl L. Chow, Pharm.D., BCPS
- and
Alan Zillich, Pharm.D.

Sunday, October 19, 2007

8:00 a.m. – 12:00 p.m.

Opening General Session

Moderator: Gary R. Matzke, Pharm.D., FCCP

ACCP President and Associate Dean for Clinical Research and Public Policy, Department of Pharmacy, Virginia Commonwealth University Richmond, Virginia

8:00 a.m.

Keynote Address—Improving Healthcare Through Pharmacy Performance Measurement: Where Are We Now and Where Do We Hope to Go?

Laura Cranston, R.Ph.

Executive Director, Pharmacy Quality Alliance, Fairfax Station, Virginia

Learning Objectives:

1. Explain the establishment and evolution of the PQA (a pharmacy quality alliance) and its current consensus-based structure.
2. Provide an overview of the status and testing of PQA's "starter measures" and the measure initiatives for 2008-2009.
3. Describe the existing and needed research activities in which PQA is engaged and to which clinical pharmacists might contribute now or in the future.
4. Provide context for the work of PQA within the larger quality initiatives of the health care system as a whole.
5. Discuss what a pharmacy provider performance reporting template and what a consumer-focused reporting template might look like.

10:30 a.m.

Therapeutic Frontiers Award Lecture—The Genome As a Tool for Clinical Pharmacy

Howard McLeod, Pharm.D., FCCP

Fred N. Eshelman Distinguished Professor, Director, UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill
Chapel Hill, North Carolina

Monday, October 20, 2008

9:15 a.m. – 10:45 a.m.

Curricular Track 1—Translational Research: Predicting Patient Response to Pharmacotherapy

Translational Research: The NIH Roadmap and Scope of Research

Moderator: Susan Goodin, Pharm.D., FCCP, BCOP

Professor of Medicine, UMDNJ/Robert Wood Johnson Medical School, Director, Division of Pharmaceutical Sciences, The Cancer Institute of New Jersey, New Brunswick, New Jersey

9:15 a.m.

The NIH Roadmap: What It Means to Clinical Pharmacy Research
Patty Slattum, Pharm.D, Ph.D.
Vice Chair for Graduate Studies, Associate Professor and Geriatric Specialist, Department of Pharmacy, Virginia Commonwealth University, Richmond, Virginia

Learning Objectives:

1. Describe why the NIH Roadmap was undertaken to re-engineer the clinical research enterprise.
2. Discuss the NIH Roadmap as it pertains to clinical pharmacy research now and in the future.
3. Cite ways in which clinical pharmacists are critical to the CTSA success.

10:00 a.m.

Translational Research: The Unique Role for Clinical Pharmacy Scientists
Julie Johnson, Pharm.D., FCCP, BCPS
Professor and Chair Dept. Pharmacy Practice, Professor of Pharmaceutics, V. Ravi Chandran Professor in Pharmaceutical Sciences, Professor of Medicine (Cardiology), Director, UF Center for Pharmacogenomics, Department of Pharmacy Practice, University of Florida, Gainesville Florida

Learning Objectives:

1. Define translational research.
2. Identify the scope of translational research as it relates to improved human health, scientific discoveries and practical applications.
3. Identify examples where new technology, models or biomarkers have predicted drug efficacy, toxicity and clinical outcomes.

10:45 a.m.

Questions and Answers

9:15 a.m. – 10:45 a.m.

Curricular Track 2—Respiratory Disease Through the Continuum of Care

Difficulty Breathing—Current Issues in the Inpatient Management of Pulmonary Disease

Moderator: David E. Nix, Pharm.D., FCCP, BCPS
Associate Professor of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, Arizona

9:15 a.m. Challenges and Emerging Strategies in Treatment of ARDS

Jon Sevransky, M.D.

Professor, Division of Pulmonary and Critical Care Medicine,
Asthma & Allergy Center, Johns Hopkins Hospital, Baltimore,
Maryland

Learning Objectives:

1. Describe the pathophysiology of ARDS.
2. Better understand the application of translational research as a means to determine therapeutic targets and therapeutic agents.

9:45 a.m. Strategies in the Inpatient Management of Acute Exacerbations of COPD

Sheryl F. Vondracek, Pharm.D., FCCP, BCPS

Associate Professor, University of Colorado Denver, Denver,
Colorado

Learning Objectives:

1. Describe the GOLD Guidelines recommendations for treatment of acute exacerbation of COPD.
2. Discuss the benefits of non-pharmacologic approaches that increase survival.

10:15 a.m.

Inhaled Antibiotic Treatment

David E. Nix, Pharm.D., FCCP, BCPS

Associate Professor of Pharmacy Practice and Science, College
of Pharmacy, University of Arizona, Tucson, Arizona

Learning Objectives:

1. Describe the delivery systems for inhaled antibiotics.
2. Know when inhaled antibiotics are appropriate treatment.
3. Describe treatment options.

9:15 a.m. – 10:45 a.m.

Curricular Track 3—Quality of Care: Will Pharmacy Have a Say?

Can Health Care Quality Be Measured?

Moderators: Rachel Couchenour, Pharm.D., BCPS
Senior Manager, sanofi-aventis, Washington D.C.

and

Mary T. Roth, Pharm.D., MHS, FCCP

Assistant Professor, School of Pharmacy, University of North
Carolina, Chapel Hill, North Carolina

9:15 a.m.

The Current State of Healthcare Quality: How the Pharmacist Can Assist

David P. Nau, Ph.D., R.Ph., CPHQ

Director, Practice Improvement, Pharmacy Quality Alliance (PQA); Associate Professor, College of Pharmacy
Martin School of Public Policy and Administration
University of Kentucky, Lexington, Kentucky

Learning Objectives:

1. Describe the current state of quality provided by the US Health Care system.
2. Gain an appreciation of current methods and measures that are used by different groups within the healthcare continuum to evaluate healthcare quality.
3. Understand the impact of the measures and identify ones that pharmacy can assist in improving.

9:45 a.m.

Quality Assessment in Pharmacy: A Review of Measures

Brad Tice, Pharm.D.

Chief Clinical Officer, PharmMD Solutions, LLC, Brentwood, Tennessee

Learning Objectives:

1. Describe how relevant indicators of quality are defined.
2. Explain how to measure quality while maintaining scientific integrity.
3. List common pitfalls to avoid when measuring quality.

10:15 a.m.

Measuring Quality of Hospital Care: Opportunities for Pharmacy

C. A. Bond, Pharm.D., FASHP, FCCP

Professor of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas

Learning Objectives:

1. Describe quality indicators for hospital care and pharmacy services.
2. Discuss steps involved in measuring quality of hospital care.
3. Explore the impact of pharmacy staffing and staffing models on quality of inpatient care.

9:15 – 10:45 a.m.

Curricular Track 4—Emergency Medicine

Evolution and Growth of Emergency Pharmacy

Moderator: Deborah Sturpe, Pharm.D., BCPS

Assistant Professor, University of Maryland, School of Pharmacy, Baltimore, Maryland

9:15 a.m.

Establishing Emergency Department Pharmacy Services: Which
Emergency Department's, What Services, and the Table for
Clinical Services

Brad Miller, Pharm.D.

Clinical Pharmacy Specialist, Emergency Medicine, Spectrum
Health, Grand Rapids, Michigan

and

Umbreen Mutaza, Pharm.D, BCPS

Program Director, Emergency Medicine Clinical Specialist,
Department of Pharmacy, The Johns Hopkins Hospital,
Baltimore, Maryland

and

Kevin O. Rynn, Pharm.D., FCCP, DABAT

Clinical Associate Professor, Ernest Mario School of Pharmacy,
Rutgers, The State University of New Jersey, Piscataway, New
Jersey

Learning Objectives:

1. Contrast the different pharmacy needs of EDs in different settings.
2. List and describe the spectrum of services that pharmacists provide within the ED setting.
3. Describe the process by which clinical services are incorporated into ED pharmacy services.

9:45 a.m.

Training Clinicians for ED Practice

Kevin O. Rynn, Pharm.D., FCCP, DABAT

Learning Objectives:

1. Describe how to establish a clerkship rotation in the ED setting.
2. Describe how to establish a specialized ED residency.

10:15 a.m.

Research Opportunities in the Emergency Department

George Delgado, Jr., Pharm.D.

Clinical Pharmacy Specialist, Detroit Receiving Hospital and
University Health Center, Department of Pharmacy Services,
Detroit, Michigan

Learning Objectives:

1. Describe the process of identifying research opportunities in the ED setting.
2. List the unique obstacles to carrying out research in the ED.
3. Explain how to successfully incorporate pharmacy students and residents in ED-based research projects.

9:15 a.m. – 10:45 a.m.

Late Breakers, I

Moderator: Peter Dumo, Pharm.D.
CEO, DumoPharm, Inc., Detroit, Michigan

Oncology Therapeutics

R. Donald Harvey III, Pharm.D., BCPS, BCOP
Assistant Professor of Hematology and Oncology, Emory University
School of Medicine, Winship Cancer Institute of Emory University,
Atlanta, Georgia

Immunology/Transplant Disease Therapeutics

R. Donald Harvey III, Pharm.D., BCPS, BCOP
Assistant Professor of Hematology and Oncology, Emory University
School of Medicine, Winship Cancer Institute of Emory University,
Atlanta, Georgia

CNS/Neurological Therapeutics

Susan C. Fagan, Pharm.D., FCCP, BCPS
Professor, Clinical and Administrative Pharmacy, University of
Georgia, Augusta, Georgia

Women's Health

Susan C. Fagan, Pharm.D., FCCP, BCPS
Professor, Clinical and Administrative Pharmacy, University of
Georgia, Augusta, Georgia

Cardiovascular Therapeutics

James E. Tisdale, Pharm.D., FCCP, BCPS
Professor, School of Pharmacy, Purdue University, Indianapolis,
Indiana

Critical Care Therapeutics

James E. Tisdale, Pharm.D., FCCP, BCPS
Professor, School of Pharmacy, Purdue University, Indianapolis,
Indiana

9:15 a.m. – 11:15 a.m.

Leadership and Advocacy

*Part of the ACCP Academy Leadership and Management Certificate
Program. For more information visit the Web site at
<http://academy.accp.com/>.*

Robert S. Beardsley, R.Ph., Ph.D.

Professor of Pharmaceutical Health Sciences Research, University of
Maryland School of Pharmacy, Baltimore, Maryland

9:15 a.m. – 11:15 a.m.

Student Peer Assessment: Making the Process Work in Your Classes

Part of the ACCP Academy Teaching and Learning Certificate Program. For more information, visit the Web site at <http://academy.accp.com/>.

Eric H. Hobson, Ph.D.

Professor and Associate Dean for Academic Affairs, Belmont University School of Pharmacy, Nashville, Tennessee

1:30 p.m. – 3:30 p.m.

Adult Medicine PRN Focus Session—Clinical Topics in Adult Medicine

Moderator: Darcie L. Keller, PharmD., BCPS

Assistant Professor, Division of Clinical Pharmacology, University of Missouri Kansas City, School of Medicine, Kansas City, Missouri

1:30 p.m.

Managing Hyperglycemia in Medically-Ill Patients

Lindsay M. Arnold, Pharm.D., BCPS

Internal Medicine Clinical Specialist, Boston Medical Center, Somerville, Massachusetts

Learning Objectives:

1. Review evidence supporting tight glycemic control outside of the ICU.
2. Evaluate benefit vs. risk of tight glycemic control outside of the ICU.
3. Identify proven strategies for achieving recommended glycemic goals.

2:00 p.m.

New Approaches to Initial Treatment of Rheumatoid Arthritis

Beth H. Resman-Targoff, Pharm.D., FCCP

Clinical Professor, Department of Pharmacy: Clinical and Administrative Sciences, University of Oklahoma, Oklahoma City, Oklahoma

Learning Objectives:

1. Discuss the benefits of an aggressive treatment-to-target strategy in the management of rheumatoid arthritis.
2. Compare the effects of initial sequential monotherapy, step-up therapy, and combination therapy for rheumatoid arthritis.
3. Describe differences in outcomes of rheumatoid arthritis treatment with early use of a biologic agent vs. conventional drugs.

2:30 p.m.

Providing Bridge Therapy in Atrial fibrillation
Kelly M. Summers, Pharm.D., BCPS
Assistant Professor of Pharmacotherapy, School of Pharmacy,
University of Maryland, Baltimore, Maryland

Learning Objectives:

1. Identify the need for emergent anticoagulation in patients with atrial fibrillation.
2. Review the evidence supporting bridge therapy in atrial fibrillation.
3. Evaluate different therapeutic options.

3:00 p.m.

Continuous Infusion vs. Intermittent Diuretic Dosing
Alexander K. McDonald, Pharm.D., BCPS
Clinical Pharmacy Specialist, Spartanburg Regional Healthcare
System, Spartanburg, South Carolina

Learning Objectives:

1. Compare pharmacokinetic and pharmacodynamic differences of continuous infusion vs. intermittent diuretic dosing.
2. Describe differences in outcomes in patients treated with intermittent and continuous infusion diuretics.
3. Discuss appropriate indications, drug regimens, and required monitoring for use of continuous infusion diuretics.

1:30 p.m. – 3:30 p.m.

Clinical Administration PRN Focus Session—Justifying and Expanding Clinical Pharmacy Services: Economic Value and Case Studies

Moderator: Bob L. Lobo, Pharm.D., BCPS
Assistant Director, Clinical Pharmacy, Methodist Healthcare,
Germantown, Tennessee

1:30 p.m.

Evidence Base for Justification of Clinical Pharmacy Services
Alexandra Perez, Pharm.D.
Research Fellow, Center for Pharmacoeconomic Research and
Department of Pharmacy Practice, College of Pharmacy,
University of Illinois at Chicago, Chicago, Illinois

Learning Objectives:

1. Review recent published evidence supporting the economic value of CPS.
2. Identify the pharmacy services and settings of care with the most published evidence for economic value.
3. Identify the pharmacy services and settings of care where further research is needed on the economic value.
4. Describe how the published literature can be used to justify and expand clinical pharmacy services.

2:15 p.m.

Justification of CPS in the Emergency Department
Lisa A. Saubermann, Pharm.D., BCPS
Associate Director – Clinical Pharmacy Services, Strong Health
Pharmacy, University of Rochester Medical Center, Rochester,
New York

Learning Objectives:

1. Discuss published evidence for CPS in ED.
2. Describe the setting, goals, challenges and processes related to development and implementation of the CPS.
3. Discuss the impact of the CPS and how internal and external data were used to justify the CPS.

2:45 p.m.

Justification of Inpatient Anticoagulation
Michael P. Gulseth, Pharm.D., BCPS
Assistant Professor, Department of Pharmacy Practice and
Pharmaceutical Sciences, College of Pharmacy, University of
Minnesota, Duluth, Minnesota

Learning Objectives:

1. Briefly, discuss published evidence for this CPS.
2. Describe the setting, goals, challenges and processes related to development and implementation of the CPS.
3. Discuss the impact of the CPS and how internal and external data were used to justify the CPS.

3:15 p.m.

Questions and Answers

1:30 p.m. – 3:30 p.m.

**Critical Care PRN Focus Session—A Case of Critical Care
Dilemmas: Surviving Sepsis**

Moderator: Lance J. Oyen, Pharm.D., BCPS, FCCM
Assistant Director, Clinical Services, Pharmacy Department,
Assistant Professor, Mayo College of Medicine,
Clinical Pharmacist – Surgery/Trauma ICU, Mayo Clinic,
Rochester, Minnesota

1:30 p.m.

Hemodynamic Reversal of Septic Shock
Seth R. Bauer, Pharm.D., BCPS
Anemia Management Clinical Specialist, Cleveland Clinic,
Cleveland, Ohio

Learning Objectives:

1. Incorporate of Surviving Sepsis best practices where appropriate.
2. Address Catecholamine vs Vasopressin vs Steroids and their place in therapy.

2:10 p.m.

Timing Is Everything in the Therapeutics of the Critically Ill
Eric W. Mueller, Pharm.D.
Clinical Pharmacy Specialist, Critical Care,
Director, Critical Care Pharmacy Residency Program
The University Hospital; Adjunct Assistant Professor of Pharmacy
Practice, University of Cincinnati, Cincinnati, Ohio

Learning Objectives:

1. Incorporate of Surviving Sepsis best practices where appropriate.
2. Address the importance of timing and sequence of interventions: antibiotics, resuscitation, and the difference between success and failure of therapies dependent on when given.

2:50 p.m.

Delirium and Its Treatment in the Critically Ill
Ishaq Lat, Pharm.D., BCPS
Clinical Pharmacy Specialist, Critical Care, University of Chicago
Medical Center, Chicago, Illinois

Learning Objectives:

1. Incorporate of Surviving Sepsis best practices where appropriate.
2. Summarize diagnostic tools and haldol vs. other agents.

1:30 p.m. – 3:30 p.m.

**GI/Liver/Nutrition PRN Focus Session—Current
Pharmacotherapy Topics in Gastroenterology**

Moderator: David Foster, Pharm.D.
Assistant Professor of Pharmacy Practice
Purdue University, School of Pharmacy and Pharmaceutical Sciences
Adjunct Assistant Professor of Medicine, Indiana University School
of Medicine, Indianapolis, Indiana

1:30 p.m.

New Safety Concerns with PPI Therapy
John W. Devlin, Pharm.D., BCPS, FCCM
Clinical Pharmacist, Medical Intensive Care Unit, Associate
Professor of Pharmacy, Tufts-New England Medical Center
Northeastern University School of Pharmacy, Boston,
Massachusetts

Learning Objectives:

1. Discuss the relationship of long-term PPI therapy to hip fracture risk.
2. Discuss the association of acid suppression with PPIs and infectious complications.
3. Address the controversy regarding the potential relationship between PPI use and cardiovascular mortality.

2:30 p.m.

Pancreatic Enzyme Pharmacotherapy
Robert Kuhn, Pharm.D.
Professor, Pharmacy Practice and Science, College of
Pharmacy, University of Kentucky Medical Center, Lexington,
Kentucky

Learning Objectives:

1. Discuss the current regulatory issues surrounding FDA approval of pancreatic enzyme preparations.
2. Discuss how clinicians should best choose a pancreatic enzyme formulation, dosage and administration method for particular patients.

1:30 p.m. – 3:30 p.m.

ACCP Advocates Training Session: Presidential Politics, Health Reform and Grassroots Action

2008 is a pivotal election year while 2009 could be the year for significant healthcare reform. Join us to learn how you can be a more effective advocate for pharmacy and healthcare issues.

This session is open to all attendees, but ACCP Advocates are strongly encouraged to attend.

Please contact John McGlew at jmclew@accp.com for more information.

1. Understand ACCP's legislative proposal to expand opportunities for Medicare beneficiaries to receive the patient-care services of pharmacists.
2. Describe ACCP Advocates grassroots efforts in Washington, DC and state capitols.
3. Assess your skills as a lobbyist with our hill visit training.

Faculty

John McGlew, M.A.,
Assistant Director, American College of Pharmacy, Washington, D.C.

1:30 p.m. – 4:30 p.m.

Oncology Pharmacy Specialty Sessions, Part I

Part of the professional development program for recertification of Board Certified Oncology Pharmacists, approved by the Board of Pharmaceutical Specialties and cosponsored by ACCP, the American Society of Health-System Pharmacists (ASHP), and the Hematology/Oncology Pharmacy Association (HOPA). Part II will be presented on Tuesday, October 21, from 1:30 p.m. to 4:30 p.m. Participants must attend all six hours of programming to be eligible to complete the Web-based post test for oncology recertification credit. Partial credit is not available. The post test fee is \$45. After the Annual Meeting, program participants will receive e-mail instructions to access the test.

Moderator: Chris Fausel, Pharm.D., BCOP
Clinical Pharmacist, Indiana University Hospital, Indianapolis, Indiana

1:30 p.m.

Updates in Chronic Myeloid Leukemia
Chris Fausel, Pharm.D., BCOP, BCPS

Learning Objectives:

1. Discuss state of the art treatment algorithms for CML including cyto-reduction, tyrosine-kinase inhibition, and hematopoietic stem cell transplantation.
2. Distinguish between the roles of imatinib and second-generation therapies for treatment of CML.

2:30 p.m.

Updates on Prostate Cancer
Barry R. Goldspiel, Pharm.D., BCPS, BCOP
Assistant Director, National Institute of Health Clinical Center,
Bethesda, Maryland

Learning Objectives:

1. Describe the current standard of care for a patient with advanced prostate cancer.
2. Discuss potential treatment options for a patient with advanced prostate cancer who has failed initial therapy.
3. Explain the biologic rationale for studying vaccines in prostate cancer patients
4. Formulate a treatment and monitoring plan to prevent metabolic complications in a patient with prostate cancer receiving androgen deprivation therapy.

3:30 p.m.

Novel Treatment Strategies in Myelodysplastic Syndromes
R. Donald Harvey III, Pharm.D., BCPS, BCOP
Assistant Professor of Hematology and Oncology, Emory
University School of Medicine, Winship Cancer Institute of Emory
University, Atlanta, Georgia

Learning Objectives:

1. Describe the role of the International Prognostic Scoring System (IPSS) in therapeutic decision-making in MDS.
2. Analyze the clinical trial results of hypomethylating agents in the treatment of low, intermediate, and high risk MDS.
3. Differentiate individualized therapy for patients who are positive for 5q- and HLA-DR15 typing.
4. Evaluate the outcomes and role of nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) in patients with MDS.
5. Discuss utilization of supportive care therapies in patients with MDS, with a focus on red cell support options, iron chelation, and colony stimulating factors.

1:30 p.m. – 5:30 p.m.

Personal Leadership Development

Part of the ACCP Academy Leadership and Management Certificate Program. For more information visit the Web site at <http://academy.accp.com/>.

Faculty: *Robert E. Smith, Pharm.D.*

Professor and Head, Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn University, Alabama

and

Peter Hurd, Ph.D.

Professor of Pharmacy Administration, Director of Pharmaceutical Sciences and Liberal Arts Division, Assistant Dean for Assessment, St. Louis College of Pharmacy, St. Louis, Missouri

Learning Objectives:

1. Assume responsibility for achieving a full and balanced professional career.
2. Construct and use a personal mission statement as a guide to professional achievement.
3. Balance personal and professional career planning.

1:30 p.m.

Taking Responsibility for Self-Leadership

2:40 p.m.

Break

2:55 p.m.

The Personal Mission Statement

4:05 p.m.

Time Management or Life Leadership

5:15 p.m.

Question and Answer

1:30 p.m. – 5:30 p.m.

Implementing Teaching and Learning Strategies

Part of the ACCP Academy Teaching and Learning Certificate Program. For more information visit the Web site at <http://academy.accp.com/>.

Moderator: Thomas D. Zlatic, Ph.D.
Professor, St. Louis College of Pharmacy, St. Louis, Missouri

Faculty: Dana Hammer, Ph.D.
Director, Bracken Pharmaceutical Care Learning Center, University of Washington School of Pharmacy, Minneapolis, Minnesota

Eric H. Hobson, Ph.D.
Professor and Associate Dean for Academic Affairs, Belmont University School of Pharmacy, Nashville, Tennessee

Chris Lynch, Pharm.D.
Associate Professor, Southern Illinois University–Edwardsville School of Pharmacy, Edwardsville, Illinois

Learning Objectives:

1. Describe challenges to employing select educational strategies.
2. Discuss methods to mitigate these challenges.
3. Review examples of student and faculty incivilities.

1:30 p.m.	Introduction
1:35 p.m.	Instructional Strategy Inventory
2:20 p.m.	The Enhanced Lecture
2:40 p.m.	Analysis of “Did Not Work” Scenarios
3:00 p.m.	Muddiest Point
3:05 p.m.	Muddiest Point Feedback
3:35 p.m.	Break
3:50 p.m.	Experiential Teaching Introduction
4:00 p.m.	Scenario No. 1
4:30 p.m.	Scenario No. 2
5:00 p.m.	Scenario No. 3
5:30 p.m.	Question and Answer

3:45 p.m. – 5:45 p.m.

Administrative Databases

Part of the ACCP Academy Research and Scholarship Development Certificate Program. For more information visit the Web site at <http://academy.accp.com/>.

Introduction to Performing Outcomes Research Using Pharmacy Benefit Manager (PBM) Claims Data
Patrick P. Gleason, Pharm.D., FCCP, BCPS
Director of Outcomes Assessment, Prime Therapeutics LLC, Eagan, Minnesota

Catching Your Own....Use of Electronic Medical Records to Facilitate Research
Rex W. Force, Pharm.D., FCCP, BCPS
Professor of Family Medicine and Pharmacy Practice; Director of Research for the Idaho Drug Utilization Review Program, Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello, Idaho

A Primer on Conducting Healthcare Research Using "Free" Data
Donald G. Klepser, Ph.D., MBA
Assistant Professor, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska

3:45 p.m. – 5:45 p.m.

Endocrinology PRN Focus Session—Clinical Pearls in Endocrinology and Metabolism

Moderator: Brian K. Irons, Pharm.D., BCPS
Associate Professor, Head, Primary Care Division, School of Pharmacy, Texas Tech University Health Sciences Center, Lubbock, Texas

3:45 p.m.

Limitations of Insulin Sliding Scales
Natasha N. Harrigan, Pharm.D.
Assistant Professor of Pharmacy Practice, School of Pharmacy, Hampton University, Hampton, Virginia

Learning Objectives:

1. Discuss the limitations using sliding scale insulin regimens in both the out-patient and in-patient setting.
2. Review the current literature on the use of sliding scale insulin regimens.
3. Suggest alternative approaches to optimize glycemic control during hyperglycemic excursions.

4:15 p.m.

Is There a Role for a T3/T4 Combination in Thyroid Disorders
Jennifer Clements, Pharm.D.
Assistant Professor of Pharmacy Practice, Bernard J. Dunn School of Pharmacy, Winchester, Virginia

Learning Objectives:

1. List the types of available combination therapies in treating hypothyroidism.
2. Discuss the rationale for using combination therapy, including types of patients where T3 may be beneficial.
3. Discuss patients in which to avoid combination treatment and possible side effects.

4:45 p.m.

Pramlintide and Leptin Versus Pramlintide Alone in Obesity
L. Brian Cross, Pharm.D., C.D.E
Associate Professor, College of Pharmacy, University of
Tennessee, Kingsport, Tennessee

Learning Objectives:

1. Review the role of pramlintide and leptin in obesity.
2. Describe the risks/benefits of using pramlintide and leptin versus pramlintide monotherapy.
3. Discuss patients that may benefit the most from either of these drugs or the combination.

5:15 p.m.

ACE-I / ARB Combination Therapy for Diabetic Nephropathy
Carolyn C. Brackett, Pharm.D., BCPS
Associate Professor, College of Pharmacy, The Ohio State
University, Columbus, Ohio

Learning Objectives:

1. Describe the rationale behind ACE-I/ARB combination therapy for diabetic nephropathy.
2. Review the current literature on the use of ACE-I/ARB combination therapy.
3. Discuss patients where this combination may be advantageous and in whom it may be detrimental.

3:45 p.m. – 5:45 p.m.

Geriatrics PRN Focus Session—The Great Geriatric Debate: To Treat or Not to Treat

Moderator: Heather L. Bieber, Pharm. D., CGP, BCPS
Geriatric Clinical Pharmacist, Lake City Veterans Affairs Medical
Center, Gainesville, Florida

3:45 p.m.

Antihypertensives: Pro Side
Mandy R. Torres, Pharm.D., BCPS
Clinical Pharmacy Specialist, Geriatrics, Stratton VA Medical
Center, Albany, New York

Learning Objectives:

1. Understand antihypertensive use in the 8th decade of life and older.
2. Evaluate the evidence for treatment.
3. Review new literature in support of treatment.
4. Discuss reasons to treat.

4:15 p.m.

Antihypertensives: Con Side
James E. Tisdale, Pharm.D., FCCP, BCPS
Professor, School of Pharmacy, Purdue University, Indianapolis, Indiana

Learning Objectives:

1. Understand antihypertensive use in the 8th decade of life and older.
2. Evaluate evidence for no treatment and discontinuation of treatment.
3. Review new literature not supporting treatment.
4. Discuss reasons to not treat or to discontinue.

4:45 p.m.

Acetylcholinesterase Inhibitors: Pro Side
Jena L. Ivey, Pharm.D., BCPS
Clinical Assistant Professor, Division of Pharmacy Practice and Experiential Education, Clinical Assistant Professor, Division of Geriatrics, School of Medicine, University of North Carolina, Chapel Hill, North Carolina

Learning Objectives:

1. Understand Acetylcholinesterase Inhibitors use in the 8th decade of life and older.
2. Evaluate the evidence for treatment.
3. Review new literature in support of treatment.
4. Discuss reasons to treat.

5:15 p.m.

Acetylcholinesterase Inhibitors: Con Side
Norma J. Owens, Pharm.D., FCCP, BCPS
Professor and Chair, Pharmacy Department, University of Rhode Island, Providence, Rhode Island

Learning Objectives:

1. Understand Acetylcholinesterase use in the 8th decade of life and older.
2. Evaluate evidence for no treatment and discontinuation of treatment.
3. Review new literature not supporting treatment.
4. Discuss reasons to not treat or to discontinue.

3:45 p.m. – 5:45 p.m.

Infectious Diseases PRN Focus Session—Tools Available for Optimizing Prevention, Diagnosis, and Treatment of Infectious Diseases

Developed in cooperation with members of the Society of Infectious Diseases Pharmacists (SIDP)

Moderator: Melinda Neuhauser, Pharm.D., M.P.H.
Clinical Pharmacy Specialist, Infectious Diseases; VA Pharmacy Benefits Management Services, Hines, Illinois

3:45 p.m.

Hospital-Acquired Infection Legislative Update—Putting Policy Into Practice
Kristine M. Kuper, Pharm.D., BCPS
Clinical Director, Infectious Disease, Cardinal Health Center for Safety and Clinical Excellence, Houston, Texas

Learning Objectives:

1. Identify recent legislative activities at both the state and national level related to HAIs.
2. Discuss how changes in reimbursement associated with HAIs will impact hospitals.
3. Recognize the current methods for tracking nosocomial infections.
4. Identify best practices in US Healthcare that have successfully impacted HAI rates.

4:25 p.m.

Update in Diagnostic Tools in Infectious Diseases
Julie A. Ribes, M.D., Ph.D.
Medical Director for Reproductive Laboratory Science and Clinical Laboratory Sciences; Associate Professor of Pathology; Director of Clinical Microbiology, Department of Pathology; Associate Member of the Graduate Faculty, University of Kentucky, Lexington, Kentucky

Learning Objectives:

1. Summarize existing and new diagnostic tools utilized in identifying multi-drug resistant organisms.
2. Discuss the role of newly introduced diagnostic tools in isolating organisms through direct specimens.

5:05 p.m.

Choosing a Clinical Decision Support System for Antimicrobial Stewardship and Considerations for Implementation
Elizabeth D. Hermsen, Pharm.D., MBA, BCPS
Antimicrobial Specialist and Research Associate, The Nebraska Medical Center, Omaha, Nebraska

Learning Objectives:

1. Review the benefits associated with the use of clinical decision support systems (CDSSs) in regard to antimicrobial stewardship.
2. Identify steps in the decision-making/purchase process including key stakeholders, securing funding, and vendor analysis.
3. Discuss the implementation process including anticipation of barriers, tips for success, and potential uses for a CDSS.

3:45 p.m. – 5:45 p.m.

Women's Health PRN Focus Session—Treatment of Medical Conditions in Pregnancy

Moderator: Patricia Wigle, Pharm.D.

Associate Professor, James L. Winkle College of Pharmacy,
University of Cincinnati, Cincinnati, Ohio

Learning Objectives:

1. Recognize the symptoms of depression during pregnancy as well as the risk factors for depression during pregnancy.
2. Weigh the risks and benefits of treating depression during pregnancy.
3. Summarize the literature surrounding the safety of antidepressants during pregnancy.
4. Delineate the patient counseling points that should be emphasized when recommending antidepressant treatment during pregnancy.
5. Using 2008 guidelines, describe the criteria for recommending venous thromboembolism (VTE) prophylaxis for pregnant patients.
6. Design a monitoring plan for pregnant patients on antithrombotic treatment.
7. Develop an antithrombotic regimen for the transition from the antepartum to the postpartum period.
8. Describe the maternal and fetal risks of poorly controlled asthma during pregnancy.
9. Recognize the signs and symptoms of asthma and differences in clinical presentations.
10. List the National Asthma Education and Prevention Program (NAEPP) preferred pharmacologic agents for treating exacerbations and long-term control of persistent asthma, including their risks during pregnancy.

3:45 p.m.

Management of Hypertension in Pregnancy

Joseph J. Saseen, Pharm.D., FCCP, BCPS

Associate Professor, School of Pharmacy, University of Colorado
Denver, Denver, Colorado

4:15 p.m.

Management of Depression in Pregnancy

Kelly C. Lee, Pharm.D., BCPP

Assistant Professor, Skaggs School of Pharmacy and
Pharmaceutical Sciences, University of California – San Diego,
San Diego, California

4:45 p.m. Management of Thromboembolic Disease in Pregnancy
Kimberly A. Thrasher, Pharm.D., FCCP, BCPS
Associate Director of Pharmacotherapy, Department of
Pharmacotherapy, South East AHEC, Wilmington, North Carolina

5:15 p.m. Management of Asthma in Pregnancy
Leslie Hendeles, Pharm.D.
Professor of Pharmacy and Pediatrics, Department of Pharmacy
Practice, University of Florida, College of Pharmacy, Gainesville,
Florida

Tuesday, October 21, 2008

10:15 a.m. – 11:45 a.m. **Curricular Track 1—Translational Research: Predicting Patient Response to Pharmacotherapy**

Clinical Translational Science Awards and the Impact of Education and Training: Keys to Future Success

Moderators: Jimmi Hatton, Pharm.D, FCCP, FCCM, BCNSP
Department Chair and Professor, Pharmacy Practice and Science,
University of Kentucky, Louisville, Kentucky

10:15 a.m. Training Clinical Pharmacists Today and into the Future: the Role Our Schools and Colleges Will Play
Christine A. Sorkness, Pharm.D.,
Associate Director and Interim Director of the Center for the Study of Culture Diversity in Healthcare, University of Wisconsin, Madison, Wisconsin

Learning Objectives:

1. Define the CTSA award.
2. List the ways in which the CTSA will impact new pathways of discovery, research teams of the future, and re-engineering the clinical research enterprise.
3. Discuss how a national consortium, funded through CTSA's, is transforming how clinical and translational research is conducted, ultimately enabling researchers to provide new treatments more efficiently and quickly to patients.

11:00 a.m.

Enhanced Investigator Training for Clinical Pharmacists: What Options Are There?

Lynda Welage, Pharm.D., FCCP

Professor and Associate Director, College of Pharmacy, Co-Director Education, Career Development and Mentoring Programs, Michigan Institute for Clinical Health Research, University of Michigan, Ann Arbor, Michigan

Learning Objectives:

1. Discuss the impact of the CTSA on Pharm.D. student training and post-Pharm.D. training.
2. Identify whether you may qualify for NIH loan repayment for clinical researchers.
3. Identify local mechanisms for enhanced training and education in clinical pharmacy research through CTSA and other venues.

10:15 a.m. – 11:45 a.m.

Curricular Track 2—Respiratory Disease Through the Continuum of Care

Breathing Easy: Management of Pulmonary Disease in the Ambulatory Setting

10:15 a.m.

Integrating the 2007 NAEP Asthma Diagnosis and Treatment Guidelines into Patient Care: the Role of the Pharmacist

Kathryn V. Blake, Pharm.D, BCPS, FCCP

Senior Research Scientist, Center for Pediatric Pharmacology Research, Nemours Children's Clinic, Jacksonville, Florida

Learning Objectives:

1. Describe the approach to treating asthma as detailed in the 2007 Asthma Treatment Guidelines.
2. Provide the rationale for the importance of ICS in the treatment of asthma.
3. Describe a method for implementing the guidelines into practice.

10:45 a.m.

Inhaled Corticosteroids Should Be Considered Standard Therapy for Patients Receiving Regular Treatment with a Long-acting Bronchodilator (Pro vs. Con Debate)

Mary Roederer, Pharm.D., BCPS

Clinical Assistant Professor, Department of Pharmacy, University of North Carolina, Chapel Hill, North Carolina

and

Dennis Williams, Pharm.D., FCCP, BCPS

Associate Professor, Department of Pharmacy, University of North Carolina, Chapel Hill, North Carolina

Learning Objectives:

1. Discuss the benefits of steroids in COPD as they relate to mortality, prevention of exacerbations, and quality of life
2. Outline the important recent data surrounding the use of corticosteroids in exacerbations of COPD.
3. Determine whether use of PO or parenteral steroids is the best option.

11:15 a.m.

Multi-Drug Resistant TB: An Update on Treatment Options and Management

Charles Peloquin, Pharm.D.

Director, Infectious Disease, Pharmacokinetics Laboratory, National Jewish Medical and Research Center, Denver, Colorado

Learning Objectives:

1. Describe the magnitude of the problem, the epidemiology of resistance.
2. Learn mechanisms to halt the spread of resistance.
3. Describe an approach to treatment.

10:15 a.m. – 11:45 a.m.

Curricular Track 3—Quality of Care: Will Pharmacy Have a Say?

Health Care Policy and Quality: Your Vote Counts

Moderators: C. Ed Webb, Pharm.D.

Director of Governmental Affairs, American College of Clinical Pharmacy, Washington, D.C.

And

Anna Legreid Dopp, Pharm.D.

Clinical Assistant Professor, School of Pharmacy, University of Wisconsin, Madison, Wisconsin

10:15 a.m. Health Care Platform and Impact on Quality: Democratic Health Care Policy
Anna Legreid Dopp, Pharm.D.

Learning Objectives:

1. Describe the key components of Democratic Health Care Policy.
2. Describe the likely impact of democratic policy on accessibility and quality of care.

10:45 a.m. Health Care Platform and Impact on Quality: Republican Health Care Policy
Leigh Ann Ross, Pharm.D., BCPS
Assistant Professor, University of Mississippi Medical Center, Jackson, Mississippi

Learning Objectives:

1. Describe the key components of Republican Health Care Policy.
2. Describe the likely impact of republican policy on accessibility and quality of care.

11:15 a.m. Health Care for the 111th Congress
Tihisha M. Rawlins
Associate State Director, Grassroots Initiatives, AARP, Louisville, Kentucky

Learning Objectives:

1. Discuss the impact of the both democratic and republican policy on healthcare as a business and a profession.
2. List the opportunities and risks for pharmacists in both democratic and republican health care policy.
3. List the steps to ensure your congressman, senator, governor and president are aware and supportive of the pharmacists role in health care.

10:15 a.m. – 11:45a.m.

Curricular Track 4—Emergency Medicine

Pharmacy's Clinical and Educational Role in the Emergency Department

- 10:15 a.m. Infectious Diseases in the Emergency Department: Focus on Quality Initiatives
Umbreen Mutaza, Pharm.D, BCPS
 Program Director, Emergency Medicine Clinical Specialist, Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland
- Learning Objectives:
1. List infectious diseases commonly seen in the ED and their associated quality indicators.
 2. Describe clinical and distributive initiatives essential to achieving quality indicators.
 3. Describe incentive programs and cost-savings associated with ID quality initiatives in the ED.
- 10:45 a.m. Management of Acute Bleeding in the Emergency Department
Jill A. Rebuck, Pharm.D., BCPS, FCCM
 Critical Care Clinical Care Specialist, Lancaster General Hospital, Lancaster, Pennsylvania
- Learning Objectives:
1. Discuss current strategies for volume replacement in trauma-related bleeding.
 2. Describe the role of Rh-factor VII for refractory bleeding.
 3. Develop clinical protocols for refractory bleeding.
- 11:15 a.m. Acute Psychiatric Episodes and ED Management: Panic/Anxiety, Psychosis, and Suicide/Depression
Brad Miller, Pharm.D.
 Clinical Pharmacy Specialist, Emergency Medicine, Spectrum Health, Grand Rapids, Michigan
- Learning Objectives:
1. Discuss common psychiatric disorders resulting in ED visits.
 2. Explain how acute psychiatric illness affects the management of ED treatment.
 3. Discuss the pharmacotherapy of acute psychiatric illness in the ED environment.
- 10:15 a.m. – 11:45 a.m. **Tales from the Front: Ethics and Interacting with Industry**
Moderator: Randi C. Hatton, Pharm.D., FCCP, BCPS
 Co-Director, Drug Information & Pharmacy Resource Center Shands at the University of Florida,
 Clinical Professor, University of Florida, College of Pharmacy, Gainesville, Florida

10:15 a.m.

Continuing Education and Promotional Presentation
John A. Bosso, Pharm.D.
Professor and Chair, Department of Clinical Pharmacy and Outcome Sciences, South Carolina College of Pharmacy – MUSC Campus, Charleston, South Carolina

Learning Objectives:

1. Differentiate between a promotion presentation and continuing education presentation.
2. Compare and contrast speaker responsibilities regarding content and disclosure for both CE and promotional presentation.
3. Discuss the impact of OIG and pharmaceutical industry regulations on educational quality and exchange of ideas during promotional presentations.

10:45 a.m.

Disclosure and Decision Making Bodies
Allen F. Shaughnessy, Pharm.D.
Associate Program Director, Tufts University Family Medicine Residency at Cambridge Health Alliance, Malden, Massachusetts

and

Mark S. Shaefer, Pharm.D.
Group Director, Infectious Disease Medicine Development Center, GlaxoSmithKline, RTP, North Carolina

Learning Objectives:

1. Identify common relationships that should be disclosed.
2. Discuss the impact of a conflict of interest on participation during decision making.
3. Explore how clinical experts with potential conflicts can add value to the decision-making process.

11:15 a.m.

Research, Sponsorship and Ethical Interactions
Henry Bussey, Pharm.D. FCCP, FAHA
Professor, College of Pharmacy, The University of Texas at Austin, Genesis Clinical Research and ClotCare, The Medical Park at Stone Oak, San Antonio, Texas

Learning Objectives:

1. Discuss the role of sponsoring organizations in the publication process.
2. Discuss researchers' rights in publication of a company-sponsored trial.
3. Discuss relevant author disclosure on publications.

10:15 a.m. – 11:45 a.m.

Late Breakers, II

Moderator: Peter Dumo, Pharm.D.
CEO, DumoPharm, Inc., Detroit, Michigan

10:15 a.m. – 12:15 p.m.

Health Services
Marsha Raebel, Pharm.D., FCCP, BCPS
Investigator, Kaiser Permanente, Denver, Colorado

Geriatrics
Marsha Raebel, Pharm.D., FCCP, BCPS
Investigator, Kaiser Permanente, Denver, Colorado

Infectious Disease Therapeutics
David S. Hoff, Pharm.D.
Clinical Coordinator–Critical Care, Children’s Hospitals and Clinics of
Minnesota, Minneapolis, Minnesota

Pediatric
David S. Hoff, Pharm.D.
Clinical Coordinator–Critical Care, Children’s Hospitals and Clinics of
Minnesota, Minneapolis, Minnesota

Endocrinology Therapeutics
Stuart T. Haines, Pharm.D., BCPS, FCCP
Professor, University of Maryland School of Pharmacy, Baltimore,
Maryland

Nephrology Therapeutics
Stuart T. Haines, Pharm.D., BCPS, FCCP
Professor, University of Maryland School of Pharmacy, Baltimore,
Maryland

1:15 p.m. – 3:15 p.m.

**If You Build It, They Will Come: Designing An Elective Course
for Pharmacy Students**

*Part of the ACCP Academy Teaching and Learning Certificate
Program. For more information visit the Web site at
<http://academy.accp.com/>.*

Mary T. Roth, Pharm.D., MHS, FCCP
Assistant Professor, School of Pharmacy, University of North
Carolina, Chapel Hill, North Carolina

and

S. Dee Melnyk, Pharm.D.
Clinical Assistant Professor, Durham VA Medical Center, Durham,
North Carolina

Learning Objectives:

1. Recognize key questions that need to be addressed before designing and delivering an elective course.
2. Develop a topic and outcomes for an elective course.
3. Develop a syllabus for an elective course offering.

1:15 p.m. – 3:15 p.m.

**Ambulatory Care/Pharmacokinetics and Pharmacodynamics
PRN Focus Session—The Science and Practice of
Pharmacogenetic Guided Warfarin Dosing**

Moderators: Alan J. Zillich, Pharm.D.,

Assistant Professor, Purdue University, Indianapolis, Indiana

and

Brian R. Overholser, Pharm.D.,

Assistant Professor, Purdue University, Indianapolis, Indiana

1:15 p.m.

Pharmacogenetics of Warfarin

Brian F. Gage, M.D., MSc.

Associate Professor, Department of Medicine, Washington
University, St. Louis, Missouri

Learning Objectives:

1. Describe PK/PD issues regarding warfarin use.
2. Explain the CYP 2C polymorphisms and influence on the PK of Warfarin and outcomes, including INR.

2:05 p.m.

Regulatory issues with Pharmacogenetic-guided Warfarin Dosing

Gloria R. Grice, Pharm.D., BCPS

Assistant Professor, Pharmacy Practice, Barnes-Jewish Hospital
Anticoagulation Service, Washington University, St. Louis,
Missouri

Learning Objectives:

1. Discuss regulatory issues related to pharmacogenetic guided warfarin dosing.
2. Describe FDA's current stance on pharmacogenetic guided warfarin dosing.

2:40 p.m.

Statement Against: Pharmacogenetic-guided Warfarin Dosing

Ann K. Wittkowsky, Pharm.D., BCPS

Clinical Professor, University of Washington School of Pharmacy,
Director of Anticoagulation Services, University of Washington
Medical Center. University of Washington, Seattle, Washington

Learning Objectives:

1. Discuss disadvantages of pharmacogenetic-guided warfarin therapy in clinical practice.
2. Apply patient case data to disavow use of pharmacogenetic-guided warfarin therapy.

1:15 p.m. – 3:15 p.m.

**Drug Information PRN Focus Session—Drug Information
Residency Training: An Exploratory Discussion?**

Moderator: Allison Bernknopf, Pharm.D., BCPS

Assistant Professor, Ferris State University, Kalamazoo, Michigan

1:15 p.m.

Ensuring a Cadre of Adequately Trained Drug Information Specialists?

Kelly M. Smith, Pharm.D., BCPS, FASHP

Assistant Dean, Associate Professor, College of Pharmacy, University of Kentucky, Lexington, Kentucky

Learning Objectives:

1. Describe barriers to advancing specialty training practice.
2. Describe the impact of these barriers on the specialty of drug information.

1:55 p.m.

Explore: Do ASHP residency accreditation standards and meets the needs of specialty training programs?

Kelli Garrison, Pharm.D., BCPS

Manager, Medication Use Policy and Informatics; Program Director, Drug Information Practice Residency; Clinical Assistant Professor, Department of Clinical Pharmacy and Outcome Sciences, Medical University of South Carolina Drug Information Center, Charleston, South Carolina

Learning Objectives:

1. Discuss concerns about the impact of accreditation standards on specialty practice, especially as it relates to drug information.
2. Discuss whether ASHP is the best viable route for solidifying the future of specialty practice, particularly in drug information.
3. Discuss whether alternatives to ASHP accreditation should be considered for ensuring quality post-graduate specialty training.

2:35 p.m.

How We Can Advance Post-graduate Training in Drug Information?

Michael Kendrach, Pharm.D.

Professor, Pharmacy Practice; Director, Global Drug Information Center, McWhorter School of Pharmacy, Samford University, Birmingham, Alabama

Learning Objectives:

1. Discuss methods to generate interest in the specialty.
2. Discuss how drug information specialists can work within the current environment to make specialty flourish.

1:15 p.m. – 3:15 p.m.

Immunology/Transplantation PRN Focus Session—Current Challenges in Organ Transplantation

Moderator: Lisa McDevitt, Pharm.D., BCPS

Assistant Professor, Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts

1:15 p.m.

The Highly Sensitized Transplant Candidate

James J. Thielke, Pharm.D.

Clinical Pharmacist, Transplant Care, Director, Transplant Specialty Residency Program, University of Illinois, Chicago, Illinois

Learning Objectives:

1. Describe the utility of PRA and flow cytometry.
2. Identify methods to facilitate successful transplantation including IVIG desensitization protocols.
3. Compare long-term outcomes of such patients against traditional organ transplant recipients.
4. Discuss treatment options for humoral rejection.

1:55 p.m.

Update on Infectious Complications After Organ Transplantation

Erin Wade, Pharm.D.

Clinical Pharmacy Specialist, Solid Organ Transplantation, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Learning Objectives:

1. Describe current data regarding BK polyoma virus in kidney transplant recipients.
2. Describe current data regarding CMV in organ transplant recipients.
3. Describe current data regarding fungal infections in organ transplant recipients.

2:35 p.m.

Promoting Cardiovascular Health in Transplant Recipients

Ali Olyaei, Pharm.D., BCPS

Associate Professor of Medicine, Director of Clinical Trials, Oregon Health and Sciences University, Portland, Oregon

Learning Objectives:

1. Explain the prevalence of cardiac complications in organ transplant recipients.
2. Compare and contrast the management of cardiovascular risk factors in transplant recipients versus traditional patients.

1:15 p.m. – 3:15 p.m.

Pediatric PRN Focus Session—Pediatric Pulmonary Update

Moderator: Tracy Hagemann, Pharm.D.

Associate Professor, College of Pharmacy, University of Oklahoma, Oklahoma City, Oklahoma

1:15 p.m.

Updates and Controversies in the Treatment of
Asthma and Cystic Fibrosis

H. William Kelly, Pharm.D., FCCP, BCPS

Professor Emeritus, Department of Pediatrics and Pulmonary,
University of New Mexico, Albuquerque, New Mexico

Learning Objectives:

1. Review the recent updates in the asthma and cystic fibrosis guidelines.
2. Discuss current controversies in the treatment of asthma and cystic fibrosis.
3. Discuss new medications pending approval for the treatment of asthma and cystic fibrosis.

2:15 p.m.

Drug Selection for Emerging Resistance of Pediatric Community-acquired Methicillin-resistant *Staphylococcus aureus* Pneumonia

Robert J. Kuhn, Pharm.D.

Professor, University of Kentucky Medical Center, Lexington,
Kentucky

Learning Objectives:

1. Review the epidemiology of CA-MRSA in the community setting.
2. Identify emerging patterns of *S. aureus* including alteration of the Staphylococcal cassette chromosome *mec* gene types.
3. Discuss age-appropriate empiric antibiotic strategies for community-acquired pneumonia in areas with emerging CA-MRSA.
4. Discuss antibiotic options for treating CA-MRSA.
5. Discuss the use of intrapleural thrombolytics versus video-assisted thoracic surgery (VATS) for pediatric empyema.

1:15 p.m. – 5:15 p.m.

Basics of Clinical Research

Part of the ACCP Academy Research and Scholarship Development Certificate Program. For more information visit the Web site at <http://academy.accp.com/>.

Moderator: Gary C. Yee, Pharm.D., FCCP, BCOP
Professor, University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska

Faculty:

Diane E. Beck, Pharm.D.
Director, Educational and Faculty Development, University of Florida, Gainesville, Florida

Kathleen M. Bungay, Pharm.D., M.S., FCCP
Assistant Professor, Medicine and Psychiatry • Tufts Medical Center
The Health Institute, Boston, Massachusetts

Susan C. Fagan, Pharm.D., FCCP, BCPS
Professor, Clinical and Administrative Pharmacy, University of Georgia, Augusta, Georgia

Mark A. Munger, Pharm.D., FCCP
Professor of Pharmacotherapy and Associate Dean, College of Pharmacy, University of Utah, Salt Lake City, Utah

Gary C. Yee, Pharm.D., FCCP, BCOP
Professor, University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska

Learning Objectives:

1. Name the differences between clinical, basic, and translational research.
2. Identify the basic design features that underlie traditional clinical trials.
3. List a set of steps to determine if the study design appropriate to answer the hypothesis.
4. Name mechanisms to determine if the proposed analysis plan is sound.
5. List mechanisms to avoid common biases in clinical research.
6. Create a proposal that is hypothesis driven.
7. Determine if preliminary data suggest that a hypothesis is sound.
8. Identify criteria to rate whether a hypothesis is novel.
9. Discuss issues related to subject recruitment within the projected time table.
10. Create a time table for study completion.
11. Cite ways to determine whether a new proposal represents a significant contribution to the field.
12. Appreciate the role of local and other granting agencies for junior faculty members.
13. Tailor your proposal to the likely reviewers of the funding agency.
14. Assess the appropriateness of a proposed time frame for completion of a study.
15. Appreciate the most common pitfalls and deficits identified in clinical grant submissions that result in no funding.

1:30 p.m. – 4:30 p.m.

Oncology Pharmacy Specialty Sessions, Part II

Part of the professional development program for recertification of Board Certified Oncology Pharmacists, approved by the Board of Pharmaceutical Specialties and cosponsored by ACCP, the American Society of Health-System Pharmacists (ASHP), and the Hematology/Oncology Pharmacy Association (HOPA). Part I was presented Monday, October 20, from 1:30 p.m. to 4:30 p.m. Participants must attend all six hours of programming to be eligible to complete the Web-based post test for oncology recertification credit. Partial credit is not available. The post test fee is \$40. After the Annual Meeting, program participants will receive e-mail instructions to access the test.

*Moderator: Mary Lynn McPherson, Pharm.D., BCPS, CDE
Professor, University of Maryland School of Pharmacy
Hospice Consultant Pharmacist, University of Maryland, Baltimore, Maryland*

1:30 p.m.

Update in Palliative Care

*Mary Lynn McPherson, Pharm.D., BCPS, CDE
Professor, University of Maryland School of Pharmacy
Hospice Consultant Pharmacist, University of Maryland, Baltimore, Maryland*

Learning Objectives:

1. Differentiate between levels of hospice care (routine home care, continuous home care and inpatient care) and reimbursement levels throughout the United States.
2. Describe the process of effective medication management for patients with advanced illness.
3. Describe controversial therapeutic dilemmas in caring for patients with advanced illness such as the potential for opioids to hasten death, withdrawal of ventilatory support, and the use of anticoagulants.
4. Develop a strategy for dosing methadone safely and effectively to control pain in advanced cancer patients.

2:30 p.m.

Head and Neck Cancer Updates
Sarah L. Scarpace, Pharm.D., BCOP
Assistant Professor, Pharmacy Practice, Albany College of
Pharmacy, Albany, New York

Learning Objectives:

1. Explain the advantages and disadvantages of the use of chemoradiation versus surgery for the treatment of head and neck cancers.
2. Compare and contrast the efficacy and toxicity of carboplatin- versus cisplatin- based chemotherapy regimens for head and neck cancers.
3. Differentiate the various clinical settings and associated efficacy and toxicities of monoclonal antibody regimens used in the treatment of head and neck cancer.
4. Evaluate the role of combination chemotherapy in the treatment of head and neck cancers.
5. Outline a pharmacist's approach to the management of selected supportive care issues of the head and neck cancer patient.

3:30 p.m.

The Changing Endpoints and Outcomes in the Oncology Drug Approval Process
Scott A. Soefje, Pharm.D.
Director, Pharmacy Operations, Cancer Therapy and Research Center, San Antonio, Texas

Learning Objectives:

1. Explain the changes in legislation that allow the FDA to use surrogate endpoints and outcomes for accelerated drug approval.
2. Outline the FDA requirements for accelerated drug approval for oncology products, including post marketing surveillance.
3. Compare and contrast surrogate endpoints that have been used for oncology drug approval in recent years to the traditional survival and response rate endpoints.
4. Describe examples of oncology products that have received accelerated approval, the endpoints used for approval, and the outcomes of the full approval review.
5. Explain the current FDA opinion on the use of patient reported outcomes in the drug approval process.

1:30 p.m. – 5:30 p.m.

Interpersonal Leadership

Part of the ACCP Academy Leadership and Management Certificate Program. For more information visit the Web site at <http://academy.accp.com/>.

Faculty: Robert E. Smith, Pharm.D.

Professor and Head, Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn University, Alabama

and

Peter Hurd, Ph.D.

Professor of Pharmacy Administration, Director of Pharmaceutical Sciences and Liberal Arts Division, Assistant Dean for Assessment, St. Louis College of Pharmacy, St. Louis, Missouri

Learning Objectives:

1. Describe the components of an effective strategy to implement organizational change.
2. Explain the meaning of a win/win environment in the workplace.
3. Use a win/win agreement to delegate work to another.
4. Explain the importance of seeking first to understand another before attempting to be understood.
5. Provide examples of the importance of placing value on the differences that individuals bring to a group.
6. Explain the connections between creating change, a win/win environment, careful listening, and valuing the differences between individuals.

3:30 p.m. – 5:30 p.m.

Cardiology PRN Focus Session—Battle of the Sexes: Addressing Gender Specific Differences in Cardiovascular Disease

Moderator: Robert Lee Page II, Pharm.D., FCCP, FAHA, BCPS Associate Professor of Clinical Pharmacy and Physical Medicine, Schools of Pharmacy and Medicine, University of Colorado, Aurora, Colorado

3:30 p.m.

Addressing Gender Differences in Pathophysiology and Disease Presentation

Annie I. Cheang, Pharm.D., BCPS

Assistant Professor, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia

Learning Objectives:

1. Describe the differences in the pathophysiology and disease presentation between men and women specifically addressing hypertension, acute coronary syndromes, heart failure, and atrial fibrillation.
2. Formulate and defend an opinion regarding this controversial topic.

4:00 p.m. *Femme Fatal: Trends in Gender Specific Treatment Disparities and Mortality*
Judy Cheng, Pharm.D., MPH, FCCP, BCPS
Professor of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, Clinical Pharmacist, Brigham and Women's Hospital, Boston, Massachusetts

Learning Objectives:

1. Based on published literature, describe present gender specific treatment disparities among women for hypertension, ACS, heart failure, and atrial fibrillation.
2. Highlight differences in mortality in men compared to women regarding this disease states.

4:30 p.m. *Differences in Therapeutic Guidelines Between Men and Women*
Shannon W. Finks, Pharm.D., BCPS (AQ Cardiology)
Assistant Professor, College of Pharmacy, University of Tennessee, Memphis, Tennessee

Learning Objectives:

1. Discuss national published guidelines specifically addressing the treatment of women with CVD.
2. Highlight current deficiencies in published CVD guidelines regarding the treatment of women with CVD.

5:00 p.m. *Improving the Quality of Care for Women with Heart Disease*
Anne P. Spencer, Pharm.D., BCPS (AQ Cardiology)
Cardiac Care Pharmacy Specialist
Roper St. Francis Healthcare, Charleston, SC

Learning Objectives:

1. Provide insight into current national programs attempting to address present disparities.
2. Describe possible strategies to address the present disparity.
3. Delineate the role of the pharmacist in addressing this public health concern.

3:30 p.m. – 5:30 p.m. **Education and Training PRN Focus Session—Developing the APPE Clinical Rotation: ACPE Guidelines and Beyond**
Moderator: Anna M Wodlinger Jackson, Pharm.D., BCPS
Clinical Associate Professor
Temple University, Philadelphia, Pennsylvania

3:30 p.m. *Being an Effective Preceptor—Is It in You? (Part I)*
Brian L. Erstad, Pharm.D., FCCP, BCPS
Professor, Department of Pharmacy Practice, University of Arizona, Tucson, Arizona

Learning Objectives:

1. Describe the characteristics necessary for being a good clinical preceptor.

3:50 p.m. Being an Effective Preceptor—Is It in You? (Part II)
Kimberly R. Schnacky, Pharm.D., BCPS
Director for Clinical Pharmacy Services, Orlando Veterans Affairs Medical Center, Windermere, Florida

Learning Objectives:

1. Develop a strategy for managing students from different schools of pharmacy attending clerkships at the same clinical site.

4:10 p.m. Getting Students Involved—The Balance Between Seeing and Doing
Debbie C. Byrd, Pharm.D., BCPS
Associate Professor and Assistant Dean, College of Pharmacy, University of Tennessee, Knoxville, Tennessee

Learning Objectives:

1. Determine the appropriate type and amount of clinical activities for clinical APPEs.
2. Discuss student supervision and the pros/cons of close versus minimal direct supervision.

4:50 p.m. Assessment and Evaluation—The Use of a Standard Tool in Multiple Schools and Sites
Randell E. Doty, Pharm.D.
Associate Dean for Experiential Education, Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, Florida

Learning Objectives:

1. Discuss the pros/cons of a uniform evaluation tool.
2. Discuss whether a uniform evaluation tool would be practical and possible to implement among different pharmacy schools.

3:30 p.m. – 5:30 p.m.

Health Outcomes PRN Focus Session—Quality and Effectiveness of MTM Programs: What to Measure and How to Do It

Moderator: Brenda Marie Parker, Pharm.D.
Clinical Pharmacist, Humana, Prospect, Kentucky

- 3:30 p.m. Evaluating MTM Services: Outcomes of Interest to Payers and Policy Makers
Scott R Smith, R.Ph., Ph.D.
Director, Pharmaceutical Outcomes Research, Agency for Healthcare Research and Quality, Center for Outcomes and Evidence, Rockville, Maryland
- Learning Objectives:
1. Describe outcomes of interest to AHRQ and other policy makers.
 2. Describe AHRQ's national quality measures.
 3. Provide and update of AHRQ's research agenda.
- 4:00 p.m. Lessons Learned from Measuring Outcomes of MTM Services
Daniel Touchette, Pharm.D., M.A.
Assistant Professor, University of Illinois, College of Pharmacy, Chicago, Illinois
- Learning Objectives:
1. Describe challenges encountered in MTM evaluation.
- 4:50 p.m. Measuring Outcomes of MTM Services: How to Do It
David Nau, Ph.D.
Associate Professor, College of Pharmacy, University of Kentucky, Lexington, Kentucky
- Learning Objectives:
1. Describe how to develop a focused, measurable research question.
 2. Discuss important methodological considerations for data collection and analysis.
- 3:30 p.m. – 5:30 p.m. **Pharmaceutical Industry PRN Focus Session—Meeting Unmet Therapeutic Needs: Development of Novel Therapies and Programs by Industry**
Moderator: Margaret Noyes Essex, Pharm.D., FCCP
Pharmacist, Pfizer, Inc., New York, New York.
- 3:30 p.m. Novel Approaches to Gaps in Care
Wayne Anderson, Ph.D.
Director, Applied Genetics, GlaxoSmithKline, Research Triangle Park, North Carolina
- Learning Objectives:
1. Summarize the impact that industry has had on the development of new drugs, devices, and assays to address therapeutic challenges
 2. Describe new and innovative technologies used by industry to develop novel drugs to treat disease.

4:05 p.m. Importance of Medication Adherence in Improving Patient Outcomes
Dorothy L. Smith, Pharm.D.
President and CEO, Consumer Health Information Corporation, McLean, Virginia

Learning Objectives:

1. Describe the factors, challenges and risks associated with medication non-adherence.
2. Discuss the drug characteristics that aim to improve medication adherence.
3. Discuss education and reminder programs, as well as numerous devices/mechanisms/programs that are under development and/or available, to enhance medication adherence.

4:40 p.m. Myths or Realities of Biotechnology and Pharma—Update and Forecast
George Fulop, M.D., M.S.
Managing Director, Capital Management, Armonk, New York

Learning Objectives:

1. Provide an analysts' perspective on the pharmaceutical/biotechnology industry.
2. Describe how a research analyst reviews a company and a drug's prospects.
3. Provide a perspective on how to determine the value of pharmaceuticals.

5:15 p.m. Questions and Answers

Wednesday, October 22, 2008

10:15 a.m. – 11:45 a.m. **Curricular Track 1—Translational Research: Predicting Patient Response to Pharmacotherapy**

NIH Roadmap from Bench to Bedside: Clinical Pharmacists in Action

Moderator: Kathleen Stringer, Pharm.D., FCCP, BCPS,
Associate Professor, College of Pharmacy, University of Michigan, Ann Arbor, Michigan

- 10:15 a.m. The Clinical Applications of Pharmacogenomics: 2008 and Beyond
Bruce C. Carleton, Pharm.D.
Director, Pharmaceutical Outcomes Programme, Children's and Women's Health Centre of British Columbia, Associate Professor, Faculties of Pharmaceutical Sciences and medicine, University of British Columbia, Senior Clinical Scientist, Child & Family Research Institute, Vancouver, Canada
- Learning Objectives:
1. Cite the areas in which pharmacogenomics have applications at the bedside.
 2. Identify ways pharmacogenomics are transforming practical clinical drug dosing strategies.
 3. List the barriers that remain to the advancement of bench to bedside care.
- 10:40 a.m. Establishing a Pharmacist Practice-based Research Network
Grace M. Kuo, Pharm.D., M.P.H.
Associate Professor of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California – San Diego, La Jolla, California
- Learning Objectives:
1. Define a practice-based research network (PBRN).
 2. Cite the necessary components of a PBRN and types of research questions addressed by this methodology.
 3. Identify mechanisms to become involved in a PBRN on a local and national level.
 4. Describe the barriers and challenges that face a national PBRN.
- 11:00 a.m. The Use of Animal Models: Applications to Patient Care
Samuel M. Poloyac, Pharm.D., Ph.D.
Associate Professor, University of Pittsburgh, Pittsburgh, Pennsylvania
- Learning Objectives:
1. Describe how advanced imaging technology is improving our understanding of the pathophysiology of disease.
 2. Describe the impact animal models have made on pharmacotherapy.
 3. Discuss the future role of pharmacists in experimental therapeutics.
- 11:20 a.m. Panel Discussion—Models of Translational Research in Action: How Well Is It Working?
Bruce C. Carleton, Pharm.D.
Grace M. Kuo, Pharm.D., M.P.H.
Samuel M. Poloyac, Pharm.D., Ph.D.

10:15 a.m. – 11:45 a.m.

Curricular Track 2—Respiratory Disease Through the Continuum of Care

Primer on Pulmonary Arterial Hypertension

Moderator: Jennifer Barrow, Pharm.D.

Adult Clinical Pharmacist, Department of Pharmacy, University of North Carolina Hospitals, Chapel Hill, North Carolina

10:15 a.m.

National Treatment Guidelines for PAH

Robert J. Jarka, Pharm.D.

Senior Medical Scientist – Cardiopulmonary
Gilead Sciences, Inc., St. Louis, Missouri

Learning Objectives:

1. Define and describe the pathogenesis of PAH.
2. Discuss risk factors of the disease.
3. Describe the classification of disease severity.
4. Discuss the recommendations of the expert panel regarding screening, early detection, and diagnosis.

11:05 a.m.

Pharmacologic Therapy for PAH

Jennifer Barrow, Pharm.D.

Learning Objectives:

1. Identify first-line therapy for PAH.
2. Describe failure to first-line treatment and provide recommendations on second-line therapies.
3. Describe the mechanisms of drugs used to treat PAH.

10:15 a.m. – 11:45 a.m.

Curricular Track 3—Quality of Care: Will Pharmacy Have a Say?

Quality Initiatives in the Real World: How Pharmacy Is Playing a Role

Moderator: Leigh Ann Ross, Pharm.D., BCPS

Assistant Professor, University of Mississippi Medical Center,
Jackson, Mississippi

10:15 a.m.

Measuring and Improving the Quality of Care—HMO Perspective:
Kaiser Permanente

Elizabeth Chester, Pharm.D., BCPS

Quality and Clinical Pharmacy Manager, Kaiser Permanente,
Aurora, Colorado

Learning Objectives:

1. Review ways the Kaiser clinical pharmacists are improving patient care.
2. Identify the changes in quality measures for patients treated by Kaiser clinical pharmacists.
3. Explore the economic impact of pharmacist-initiated quality improvement.

10:45 a.m.

Measuring and Improving the Quality of Care—Community Pharmacy Perspective: Wisconsin Pharmacy Quality Collaborative
Patrick R. Cory, Pharm.D.
Pharmacy Program Director, Unity Health Insurance, Sauk City, Wisconsin
Deputy Director, Center for Drug Policy, University of Wisconsin Hospital & Clinics, Madison, Wisconsin

Learning Objectives:

1. Describe the rationale and establishment of the pharmacy collaborative.
2. Describe the reimbursement model implemented to support the provided clinical services.
3. Describe the impact of the service provided on quality of care.

11:15 a.m.

The Pharmacy Quality Alliance
David P. Nau, Ph.D., R.Ph., CPHQ
Director, Practice Improvement
Pharmacy Quality Alliance (PQA)
Associate Professor, College of Pharmacy
Martin School of Public Policy & Administration
University of Kentucky, Lexington, Kentucky

Learning Objectives:

1. Describe the mission, structure and goals of the Pharmacy Quality Alliance.
2. List the ongoing projects supported by the Pharmacy Quality Alliance.
3. Describe how the Pharmacy Quality Alliance can solidify the pharmacist's role in health care quality.

10:15 a.m. – 11:45 a.m.

**Hematology and Oncology PRN Focus Session—Oral
Chemotherapy: Outcomes, Advantages, and Challenges**
*Supported by an educational grant from Genentech BioOncology and
OSI Oncology*

Moderator: David Baribeault, B.S., BCOP
Pharmacy Clinical Coordinator - Hematology/Oncology; Director - Hematology/Oncology Residency Program; Coordinator - Indigent Patient Medication Access Program, Boston Medical Center, Boston, Massachusetts

10:15 a.m.

Oral chemotherapy: Novel Agents with Better Outcomes?
Susan Goodin, Pharm.D., FCCP, BCOP
Professor of Medicine, UMDNJ/Robert Wood Johnson Medical School, Director, Division of Pharmaceutical Sciences, The Cancer Institute of New Jersey, New Brunswick, New Jersey

Learning Objectives:

1. Describe the mechanism of action of currently available oral chemotherapy agents.
2. Discuss the efficacy of oral vs. parenteral chemotherapeutic agents in the treatment of cancer.
3. Discuss the known and potential drug interactions with oral chemotherapy agents.
4. Discuss the mechanism of action of oral chemotherapy agents in development.

11:00 a.m.

A Multi-disciplinary Approach to Developing a Best-practice Model for the Use of Oral Chemotherapeutic Agents
Niesha Griffith, M.S., R.Ph.
Director of Pharmacy, The James Cancer Hospital at Ohio State University Medical Center, Columbus, Ohio

Learning Objectives:

1. Identify challenges and advantages associated with the use of oral chemotherapeutic agents.
2. Evaluate opportunities for pharmacist and nursing involvement in the monitoring, education and management of side effects of oral chemotherapeutic agents.
3. Define methods for ensuring safety checks when oral chemotherapeutic agents are prescribed, dispensed and administered.
4. Evaluate opportunities for pharmacist involvement in improving access and adherence to oral chemotherapeutic agents.